First Successful Clinical Implantation of Transcatheter Pulmonary Valve VenusP-Valve was Successfully Completed in Brazil

Food and Healthcare Press Releases Monday December 25, 2017 09:05
SAO PAULO--25 Dec--PRNewswire/InfoQuest

On December 19, 2017, local time, 4 clinical implantations of transcatheter pulmonary valve VenusP-Valve were successfully completed in Brazil by Professor Carlos Pedra from Dante Pazzanese Institute of Cardiovascular Technology in Sao Paulo, Brazil.

After Chile and Argentina, Brazil becomes the third Latin American country to apply the valve of Venus Medtech (Hangzhou) Inc. It also marks the first application of China-made heart valves in Brazilian history.

At present, in every 10,000 newborns in the world, there are 16 newborns that will need surgery because of congenital heart defects. This kind of surgery can cause mass pulmonary regurgitation. Currently the interventional pulmonary valve products in the global market can only treat patients with special anatomical structure and light illness. As a result, a large number of patients with complex anatomical structure and poor right heart function are in urgent need of an interventional pulmonary valve product that could treat different anatomical structure and be operated with ease, safety and stability.

Venus Medtech (Hangzhou) Inc. has developed and manufactured transcatheter pulmonary valve VenusP-Valve, the world's first self-expanding interventional pulmonary valve. With unique double trumpet-shaped designs and laser cutting technology for valve stent, VenusP-Valve is endowed with a strong radial support force, stable anchoring, and easy release. No movement or displacement will occur during the release process. It can meet the needs of pulmonary arteries with different anatomical structures and features the only interventional pulmonary valve in the world that can treat patients with a large size of right ventricular outflow tract.

After the first successful human implantation by Academician Ge Junbo in Zhongshan Hospital, Shanghai on May 25, 2013, VenusP-Valve has entered more than 20 countries in Asia, Europe and America. At present, the clinical trial of the Chinese Food and Drug Administration (CFDA) has been finished; the process of European CE clinical trial has entered more than half of the period; communication with the United States' Food and Drug Administration (FDA) has been completed, with the start of the clinical trial before launching in USA. It is hoped that VenusP-Valve, with superior clinical results, can be approved as early as possible to provide optimal treatment for more patients.

Photo - https://photos.prnasia.com/prnh/20171222/2021378-1
Caption - First Successful Clinical Implantation of Transcatheter Pulmonary Artery Valve Venus P-Valve in Brazil

Latest Press Release

Michel Orsinger Assumes Role as Chairman of Limacorporate#s Advisory Board

LimaCorporate is pleased to announce that Michel Orsinger, Board Member of LimaCorporate's Advisory Board, will assume the role of Chairman of the Board. Michel joined the Advisory Board mid-2017 following a long and successful global career in...

Merck and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer

Merck and Pfizer Inc. (NYSE: PFE) today announced that the Phase III JAVELIN Ovarian 200 trial evaluating avelumab* alone or in combination with pegylated liposomal doxorubicin (PLD), a type of chemotherapy, compared with PLD did not meet the...

APEC#s Rare Disease Action Plan Sets Precedent to Integrate Rare Disease Care by 2025

- Asia-Pacific Economic Cooperation (APEC) Life Sciences Innovation Forum (LSIF) Rare Disease Network comprises Rare Disease International, Queensland University of Technology and Shire (representing as industry co-chair). - Aims to define, diagnose and...

Grunenthal Acquires Averitas Pharma and Establishes Commercial Footprint in the US

Grunenthal announced today that it has acquired the US-based pharmaceutical company Averitas Pharma, thereby extending its commercial footprint to the United States. Averitas Pharma will be commercialising the pain patch Qutenza(R) (8 % capsaicin) for...

Ascensia Diabetes Care Highlights the Support That Families Provide for People With Diabetes To Mark World Diabetes Day 2018

Today, Ascensia Diabetes Care, a global leading diabetes care company, launched their campaign for World Diabetes Day 2018 to celebrate the important role of families for people with diabetes. They are publishing 38 online artworks that tell the stories...

Related Topics